Novel antibody drug conjugates targeting tumor-associated receptor tyrosine kinase ROR2 by functional screening of fully human antibody libraries using transpo-mab display on progenitor B cells

Frontiers in Immunology

Volumn 9, Issue NOV, 2018, Pages

  Hellmann, Ina ^a   Waldmeier, Lorenz ^a   Bannwarth Escher, Marie Christine ^a   Maslova, Kseniya ^a   Wolter, Fabian I ^a,b   Grawunder, Ulf ^a   Beerli, Roger R ^a  

^a NBE Therapeutics AG   (Switzerland)

^b Celonic AG   (Switzerland)

Author keywords

Antibody discovery; Antibody drug conjugate (ADC); Functional screen; Human IgG transgenic mice; Human immune library; Mammalian IgG cell display; ROR2; Transposition

Indexed keywords

ANTIBODY DRUG CONJUGATE; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 2; SORTASE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; TUMOR ANTIGEN;

AMPLICON; ANIMAL CELL; ANTIBODY SCREENING; ANTIGEN EXPRESSION; ARTICLE; CANCER THERAPY; CELL VIABILITY; CYTOTOXICITY; DNA TRANSPOSITION; EC50; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NESTED POLYMERASE CHAIN REACTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PRE B LYMPHOCYTE; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; RENAL CELL CARCINOMA; RNA EXTRACTION; SURFACE PLASMON RESONANCE; ANIMAL; C57BL MOUSE; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; NEOPLASM; PHYSIOLOGY; PRECLINICAL STUDY; SINGLE CELL ANALYSIS; TRANSGENIC MOUSE; TUMOR CELL LINE; VDJ EXON;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNIZATION; IMMUNOCONJUGATES; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOTOXINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; PRECURSOR CELLS, B-LYMPHOID; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; SINGLE-CELL ANALYSIS; VDJ EXONS;

EID: 85056354804     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.02490     Document Type: Article

References (65)

1. Lambert JM, Morris CQ. Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther. (2017) 34:1015-35. doi: 10.1007/s12325-017-0519-6
2. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495-7. doi: 10.1038/256495a0
3. Beck A. Review of antibody-drug conjugates, methods in molecular biology series. mabs (2013) 6:30-3. doi: 10.4161/mabs.27005
4. Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Publish Group (2017) 16:315-37. doi: 10.1038/nrd.2016.268
5. Rebagay G, Yan S, Liu C, Cheung NK. ROR1 and ROR2 in Human malignancies: potentials for targeted therapy. Front Oncol. (2012) 2:34. doi: 10.3389/fonc.2012.00034
6. Ford CE, Qian Ma SS, Quadir A, Ward RL. The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis. Int J Cancer (2013) 133:779-87. doi: 10.1002/ijc.27984
7. Debebe Z, Rathmell WK. Ror2 as a Therapeutic target in cancer. Pharmacol Ther. (2015) 150:143-8. doi: 10.1016/j.pharmthera.2015.01.010
8. DeChiara TM, Kimble RB, Poueymirou WT, Rojas J, Masiakowski P, Valenzuela DM, et al. Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development. Nat Genet. (2000) 24:271-4. doi: 10.1038/73488
9. Green JL, Kuntz SG, Sternberg PW. Ror receptor tyrosine kinases: orphans no more. Trends Cell Biol. (2008) 18:536-44. doi: 10.1016/j.tcb.2008.08.006
10. Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, et al. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci. (2009) 100:1227-33. doi: 10.1111/j.1349-7006.2009.01165.x
11. Wright TM, Rathmell WK. Identification of Ror2 as a hypoxia-inducible factor target in von Hippel-Lindau-associated renal cell carcinoma. J Biol Chem. (2010) 285:12916-24. doi: 10.1074/jbc.M109.073924
12. Yang CM, Ji S, Li Y, Fu LY, Jiang T, Meng FD. Ror2, a developmentally regulated kinase, is associated with tumor growth, apoptosis, migration, and invasion in renal cell carcinoma. Oncol Res. (2017) 25:195-205. doi: 10.3727/096504016X14732772150424
13. O'Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC, et al. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene (2009) 29:34-44. doi: 10.1038/onc.2009.305
14. Edris B, Espinosa I, Mühlenberg T, Mikels A, Lee CH, Steigen SE, et al. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol. (2012) 227:223-33. doi: 10.1002/path.3986
15. Bayerlová M, Menck K, Klemm F, Wolff A, Pukrop T, Binder C, et al. Ror2 Signaling and Its Relevance in Breast Cancer Progression. Front Oncol. (2017) 7:135. doi: 10.3389/fonc.2017.00135
16. Roarty K, Pfefferle AD, Creighton CJ, Perou CM, Rosen JM. Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression. Oncogene (2017) 36:5958-68. doi: 10.1038/onc.2017.206
17. Mei H, Lian S, Zhang S, Wang W, Mao Q, Wang H. High expression of ROR2 in cancer cell correlates with unfavorable prognosis in colorectal cancer. Biochem Biophys Res Commun. (2014) 453:703-9. doi: 10.1016/j.bbrc.2014.09.141
18. Kobayashi M, Shibuya Y, Takeuchi J, Murata M, Suzuki H, Yokoo S, et al. Ror2 expression in squamous cell carcinoma and epithelial dysplasia of the oral cavity. YMOE (2009) 107:398-406. doi: 10.1016/j.tripleo.2008.08.018
19. Huang J, Fan X, Wang X, Lu Y, Zhu H, Wang W, et al. High ROR2 expression in tumor cells and stroma is correlated with poor prognosis in pancreatic ductal adenocarcinoma. Sci Rep. (2015) 5:9. doi: 10.1038/srep12991
20. Oishi I, Suzuki H, Onishi N, Takada R, Kani S, Ohkawara B, et al. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells (2003) 8:645-54. doi: 10.1046/j.1365-2443.2003.00662.x
21. Yamamoto H, Yoo SK, Nishita M, Kikuchi A, Minami Y. Wnt5a modulates glycogen synthase kinase 3 to induce phosphorylation of receptor tyrosine kinase Ror2. Genes to Cells (2007) 12:1215-23. doi: 10.1111/j.1365-2443.2007.01128.x
22. Rasmussen NR, Wright TM, Brooks SA, Hacker KE, Debebe Z, Sendor AB, et al. Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer. J Biol Chem. (2013) 288:26301-10. doi: 10.1074/jbc.M113.466086
23. Cheung NK. ROR1 and ROR2 in human malignancies: potentials for targeted therapy. Front Oncol. (2012) 2:1-8. doi: 10.3389/fonc.2012.00034/abstract
24. Henry C, Hacker N, Ford C. Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis. Oncotarget (2017) 8:112727-38. doi: 10.18632/oncotarget.22559
25. Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. mAbs (2014) 5:13-21. doi: 10.4161/mabs.22854
26. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJP, Weiner LM, et al. Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors. Cancer Res. (2011) 71:2250-9. doi: 10.1158/0008-5472.CAN-10-2277
27. Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem. (2012) 287:11090-7. doi: 10.1074/jbc.M111.319764
28. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol. 15:553-537. doi: 10.1038/nbt0697-553
29. Gai SA, Wittrup KD. Yeast surface display for protein engineering and characterization. Curr Opin Struct Biol. (2007) 17:467-73. doi: 10.1016/j.sbi.2007.08.012
30. Smith ES, Shi S, Zauderer M. Construction of cDNA libraries in vaccinia virus. In: Isaacs SN, editor. Vaccinia Virus and Poxvirology. Totowa, NJ: Humana Press (2004). p. 65-75.
31. Ho M, Nagata S, Pastan I. Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc Natl Acad Sci USA. (2006) 103:9637-42. doi: 10.1073/pnas.0603653103
32. Beerli RR, Bauer M, Buser RB, Gwerder M, Muntwiler S, Maurer P, et al. Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci USA. (2008) 105:14336-41. doi: 10.1073/pnas.0805942105
33. Breous-Nystrom E, Schultze K, Meier M, Flueck L, Holzer C, Boll M, et al. Retrocyte display®; technology: generation and screening of a high diversity cellular antibody library. Methods (2014) 65:57-67. doi: 10.1016/j.ymeth.2013.09.003
34. Hughes B. Antibody-drug conjugates for cancer: poised to deliver? Nat Publish Group (2010) 9:665-7. doi: 10.1038/nrd3270
35. Hock MB, Thudium KE, Carrasco-Triguero M, Schwabe NF. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. AAPS J. (2014) 17:35-43. doi: 10.1208/s12248-014-9684-6
36. Waldmeier L, Hellmann I, Gutknecht CK, Wolter FI, Cook SC, Reddy ST, et al. Transpo-mAb display: Transposition-mediated B cell display and functional screening of full-length IgG antibody libraries. mAbs (2016) 8:726-40. doi: 10.1080/19420862.2016.1160990
37. Peng H, Nerreter T, Chang J, Qi J, Li X, Karunadharma P, et al. Mining naïve rabbit antibody repertoires by phage display for monoclonal antibodies of therapeutic utility. J Mol Biol. (2017) 429:2954-73. doi: 10.1016/j.jmb.2017.08.003
38. Stefan N, Gébleux R, Waldmeier L, Hell T, Escher M, Wolter FI, et al. Highly potent, anthracycline-based antibody-drug conjugates generated by enzymatic, site-specific conjugation. Mol Cancer Ther. (2017) 16:879-92. doi: 10.1158/1535-7163.MCT-16-0688
39. Beerli RR, Hell T, Merkel AS, Grawunder U. Sortase enzyme-mediated generation of site-specifically conjugated antibody drug conjugates with high in vitro and in vivo potency. PLoS ONE (2015) 10:e0131177-17. doi: 10.1371/journal.pone.0131177
40. Tiller T, Schuster I, Deppe D, Siegers K, Strohner R, Herrmann T, et al. A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties. mAbs (2013) 5:445-70. doi: 10.4161/mabs.24218
41. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. (2003) 21:778-84. doi: 10.1038/nbt832
42. Francisco JA. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood (2003) 102:1458-65. doi: 10.1182/blood-2003-01-0039
43. Till M, May RD, Uhr JW, Thorpe PE, Vitetta ES. An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins. Cancer Res. (1988) 48:1119-23.
44. Klussman K, Mixan BJ, Cerveny CG, Meyer DL, Senter PD, Wahl AF. Secondary mAb-vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway. Bioconjugate Chem. (2004) 15:765-73. doi: 10.1021/bc049969t
45. Riedl T, van Boxtel E, Bosch M, Parren PWHI, Gerritsen AF. High-throughput screening for internalizing antibodies by homogeneous fluorescence imaging of a pH-activated probe. J Biomol Screen. (2016) 21:12-23. doi: 10.1177/1087057115613270
46. Li Y, Liu PC, Shen Y, Snavely MD, Hiraga K. A cell-based internalization and degradation assay with an activatable fluorescence-quencher probe as a tool for functional antibody screening. J Biomol Screen. (2015) 20:869-75. doi: 10.1177/1087057115588511
47. Dubowchik GM, Mosure K, Knipe JO, Firestone RA. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett. (1998) 8:3347-52.
48. Schmidt MM, Thurber GM, Wittrup KD. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol Immunother. (2008) 57:1879-90. doi: 10.1007/s00262-008-0518-1
49. Quintieri L, Geroni C, Fantin M, Battaglia R, Rosato A, Speed W, et al. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Clin Cancer Res. (2005) 11:1608-17. doi: 10.1158/1078-0432.CCR-04-1845
50. Lyon RP, Meyer DL, Setter JR, Senter PD. Conjugation of Anticancer Drugs Through Endogenous Monoclonal Antibody Cysteine Residues. 1st ed. Elsevier Inc (2012).
51. Andreev J, Thambi N, Perez Bay AE, Delfino F, Martin J, Kelly MP, et al. Bispecific antibodies and antibody-drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs. Mol Cancer Ther. (2017) 16:681-93. doi: 10.1158/1535-7163.MCT-16-0658
52. Brüggemann M, Osborn MJ, Ma B, Hayre J, Avis S, Lundstrom B, et al. Human antibody production in transgenic animals. Arch Immunol Ther Exp. (2014) 63:101-8. doi: 10.1007/s00005-014-0322-x
53. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (1986) 321:522-5. doi: 10.1038/321522a0
54. Co MS, Queen C. Humanized antibodies for therapy. Nature (1991) 351:501-2. doi: 10.1038/351501a0
55. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc. (2006) 1:755-68. doi: 10.1038/nprot.2006.94
56. Sblattero D, Bradbury A. Exploiting recombination in single bacteria to make large phage antibody libraries. Nat Biotechnol. (2000) 18:75-80. doi: 10.1038/71958
57. Lee EC, Liang Q, Ali H, Bayliss L, Beasley A, Bloomfield-Gerdes T, et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat Biotechnol. (2014)1-12. doi: 10.1038/nbt.2825
58. Chen J, Alt FW. Gene rearrangement and B-cell development. Curr Opin Immunol. (1993) 5:194-200.
59. Kitamura D, Kudo A, Schaal S, Müller W, Melchers F, Rajewsky K. A critical role of λ5 protein in B cell development. Cell (1992) 69:823-31. doi: 10.1016/0092-8674(92)90293-l
60. Melchers F, Haasner D, Grawunder U, Kalberer C, Karasuyama H, Winkler T, et al. Roles of IgH and L chains and of surrogate H and L chains in the development of cells of the B lymphocyte lineage. Annu Rev Immunol. (1994) 12:209-25. doi: 10.1146/annurev.iy.12.040194.001233
61. Rolink A, Karasuyama H, Grawunder U, Haasner D, Kudo A, Melchers F. B cell development in mice with a defective λ5 gene. Eur J Immunol. (1993) 23:1284-8. doi: 10.1002/eji.1830230614
62. Kitamura D, Roes J, Kühn R, Rajewsky K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature (1991) 350:423-26. doi: 10.1038/350423a0
63. Sblattero D, Bradbury A. A definitive set of oligonucleotide primers for amplifying human V regions. Immunotechnology (1998) 3:271-8.
64. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods (2008) 329:112-24. doi: 10.1016/j.jim.2007.09.017
65. Berry JD, Rutherford J, Silverman GJ, Kaul R, Elia M, Gobuty S, et al. Development of functional human monoclonal single-chain variable fragment antibody against HIV-1 from human cervical B cells. Hybrid Hybridom. (2003) 22:97-108. doi: 10.1089/153685903321948021